Zenas BioPharma
ZBIO
65 hedge funds and large institutions have $260M invested in Zenas BioPharma in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 14 closing their positions.
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
48% more funds holding
Funds holding: 44 → 65 (+21)
13.6% more ownership
Funds ownership: 62.25% → 75.85% (+14%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
38% less capital invested
Capital invested by funds: $419M → $260M (-$159M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.9M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$7.02M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.11M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$6.24M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.71M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.4M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.54M |
| 5 |
Goldman Sachs
New York
|
-$1.41M |
ZBIO Hedge Fund Activity: Q4 2024 in Review
65 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q4 2024, worth a combined $260M — down 38% from $419M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ZBIO positions and 14 closed out — a net gain of 21 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $15.7M. The largest seller was Perceptive Advisors, cutting an estimated $6.24M.
- 65 institutional investors held Zenas BioPharma (ZBIO) as of Q4 2024, up from 44 in Q3 2024.
- Funds reported $260M of Zenas BioPharma stock for Q4 2024, down 38% quarter-over-quarter.
- 35 funds opened new Zenas BioPharma positions in Q4 2024 and 14 closed out, a net change of +21 holders.
- The largest Zenas BioPharma buyer in Q4 2024 was BlackRock, an estimated $15.7M added.
- The largest Zenas BioPharma seller in Q4 2024 was Perceptive Advisors, an estimated $6.24M sold.
Based on aggregated 13F filings for Q4 2024.